Reimagining Medicine slide image

Reimagining Medicine

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology Immunology Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 51 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation